Welcome to the Product Spotlight series! In this series, we delve into the innovative products offered by MDBiologix, providing you with all the information you need to optimize your clinical practice.
This edition of Product Spotlight will focus on Synolis VA, an innovative visco-analgesic solution for active patients. Synolis VA stands at the forefront of viscosupplementation technology, offering a unique combination of high molecular weight hyaluronic acid (HA) and sorbitol.
Key Features:
High molecular weight HA (2.4 MDa) for improved chrondroprotection
4% Sorbitol for enhanced HA stabilization and free radical scavenging
Patented cross-over frequency for optimal viscoelasticity that mirrors young, healthy synovial fluid
Available in 2ml and 4ml pre-filled syringes for versatile application
How does Synolis VA Work?
At the heart of Synolis VA's effectiveness is its patented cross-over frequency technology. But what does this mean for your patients?
Understanding Cross-Over Frequency: Think of cross-over frequency as a measure of how well a substance can switch between behaving like a shock-absorbing gel and a lubricating fluid. In healthy joints, synovial fluid has an ideal cross-over frequency that allows it to provide cushioning during slow movements and smooth lubrication during faster activities.
Synolis VA's Unique Advantage: Synolis VA is engineered to closely mimic the cross-over frequency of healthy synovial fluid in young adults. This means it can:
Adapt to different types of movement, providing optimal cushioning and lubrication.
Maintain its effectiveness for longer periods, extending relief for your patients.
Offer better overall joint protection, potentially slowing osteoarthritis progression.
This patented technology sets Synolis VA apart, offering a solution that truly adapts to your patients' lifestyles and activity levels.
Why Synolis VA?
Superior Mobility Enhancement Synolis VA's unique formulation mimics young, healthy synovial fluid, adapting to joint movement and significantly improving function and mobility in active patients.
Rapid and Sustained Pain Relief The sorbitol component provides quick anti-inflammatory action, while the stabilized HA ensures long-lasting comfort, offering your patients both immediate and enduring relief.
Excellent Safety Profile With an remarkably low adverse event rate (<0.002%), Synolis VA gives you and your patients peace of mind. Its biofermentation production and non-cross-linked structure contribute to its outstanding safety record.
Clinically Proven Efficacy Recent studies have shown Synolis VA's superiority in improving WOMAC scores and patient satisfaction compared to traditional HA products, especially in patients with lower baseline mobility.
Did You Know?
Synolis VA's unique sorbitol component not only stabilizes HA molecules but also acts as a free radical scavenger, potentially slowing down the degradation of cartilage in osteoarthritic joints by reducing oxidative stress and inflammation.
Learn More
Interested in incorporating Synolis VA into your practice? Contact your MD Biologix representative or visit our Synolis VA product page for detailed information, clinical studies, and ordering options.
References
Cortet, B. et al. (2021): Non-Inferiority of a Single Injection of Sodium Hyaluronate Plus Sorbitol to Hylan G-F20: A 6-Month Randomized Controlled Trial. In Advances in Therapy 38 (5), pp.2271–2283. DOI: 10.1007/s12325-021-01648-3
Cucurnia, I. et al. (2021): Patient-reported outcomes of intra-articular hyaluronic acid for osteoarthritis of the knee: a prospective and multicentric case series. In Musculoskeletal surgery 2022 Sep;106(3):303-310. Epub 2021 Jan 24. DOI: 10.1007/s12306-021-00698-8
Dott. Moretti, L. et al. (2021): Outcome clinici post infilitrazione one shot di acido ialuronico ad alto peso molecolare con aggiunta di sorbitolo in pazienti con hip diseases, follow up 6 mesi.
Migliore A, et al. (2014): Duration of symptom relief after intra-articular injection of hyaluronic acid combined with sorbitol (anti-ox-vs) in symptomatic hip osteoarthritis. Int J Immunopathol Pharmacol 2014;27:245-252. DOI: 10.1177/039463201402700211
Radenne, F. (2014): Pain relief, functional recovery and associated medical treatments reduction in large-scale population with osteoarthritis receiving injections of viscosupplement incorporating high concentration of sorbitol. Osteoarthritis and Cartilage, Volume 22, Supplement, S407, April 2014. DOI: 10.1016/j.joca.2014.02.764
Gavard, S. An innovative hyaluronic acid product for viscosupplementation in patients with osteoarthritis. Osteoarthritis and Cartilage, Volume 21, Supplement , S302-S303, April 2013.
Mongkhon, J.-M., et al. (2014): Sorbitol-modified hyaluronic acid reduces oxidative stress, apoptosis and mediators of inflammation and catabolism in human osteoarthritic chondrocytes.
Heisel, J., et al. (2012): Hyaluronic acid with sorbitol-efficacy and tolerability of intra-articular treatment for osteoarthritis of the knee. In Orthopädie und unfallchirurgie zeitschrift 1, pp. 1–7
Post Market Surveillance (PMS) Data on file.
Instructions for use (IFU)
Comments